Change in COVID-19 risk over time following vaccination with CoronaVac: A testnegative case-control study.
Brazil
CoronaVac
case-control study
covid-19
inactivated vaccine
test-negative study
vaccine
waning
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
24 Dec 2021
24 Dec 2021
Historique:
entrez:
6
1
2022
pubmed:
7
1
2022
medline:
7
1
2022
Statut:
epublish
Résumé
To estimate the change in odds of covid-19 over time following primary series completion of the inactivated whole virus vaccine, CoronaVac (Sinovac Biotech) in São Paulo state, Brazil. Test negative case-control study. Community testing for covid-19 in São Paulo state, Brazil. Adults aged 18-120 years who were residents of São Paulo state, without a previous laboratory-confirmed covid-19 infection, who received only two doses of CoronaVac, and underwent reverse transcription polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 from 17 January to 30 September 2021. RT-PCR-confirmed symptomatic covid-19 and associated hospital admissions and deaths. Cases were pair-matched to test-negative controls by age (in 5-year bands), municipality of residence, healthcare worker (HCW) status, and date of RT-PCR test (±3 days). Conditional logistic regression was adjusted for sex, number of covid-19-associated comorbidities, race, and previous acute respiratory infection. From 137,820 eligible individuals, 37,929 cases with symptomatic covid-19 and 25,756 test-negative controls with covid-19 symptoms were formed into 37,929 matched pairs. Adjusted odds ratios of symptomatic covid-19 increased with time since series completion, and this increase was greater in younger individuals, and among HCWs compared to non-HCWs. Adjusted odds ratios of covid-19 hospitalisation or death were significantly increased from 98 days since series completion, compared to individuals vaccinated 14-41 days previously: 1.40 (95% confidence interval 1.09 to 1.79) from 98-125 days, 1.55 (1.16 to 2.07) from 126-153 days, 1.56 (1.12 to 2.18) from 154-181 days, and 2.12 (1.39-3.22) from 182 days. In the general population of São Paulo state, Brazil, an increase in odds of moderate and severe covid-19 outcomes was observed over time following primary series completion with CoronaVac.
Identifiants
pubmed: 34988559
doi: 10.1101/2021.12.23.21268335
pmc: PMC8728874
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI139761
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Commentaires et corrections
Type : UpdateIn
Déclaration de conflit d'intérêts
Declaration of interests All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.
Références
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
Nat Commun. 2021 Oct 28;12(1):6220
pubmed: 34711813
Lancet. 2021 Dec 4;398(10316):2093-2100
pubmed: 34756184
Clin Infect Dis. 2020 Mar 17;70(7):1484-1486
pubmed: 31351439
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Epidemiol Infect. 2019 Nov 27;147:e306
pubmed: 31774051
Science. 2022 Jan 21;375(6578):331-336
pubmed: 34735261
N Engl J Med. 2021 Dec 16;385(25):e90
pubmed: 34551224
BMJ. 2021 Aug 20;374:n2015
pubmed: 34417194
Vaccines (Basel). 2021 Oct 12;9(10):
pubmed: 34696277
Lancet. 2022 Jan 1;399(10319):25-35
pubmed: 34942103
N Engl J Med. 2021 Dec 9;385(24):e83
pubmed: 34614327
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
Lancet Infect Dis. 2022 Jan;22(1):56-63
pubmed: 34509185
Nat Commun. 2021 Nov 4;12(1):6379
pubmed: 34737312
Lancet. 2005 Apr 16-22;365(9468):1429-33
pubmed: 15836892
Nature. 2021 Oct;598(7881):398-399
pubmed: 34650240
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Lancet Reg Health Am. 2021 Sep;1:100025
pubmed: 34386791
BMJ. 2021 Nov 24;375:e067873
pubmed: 34819275